KalVista Appoints Jeb Ledell as Chief Operating Officer
16 12월 2024 - 9:00PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that Jeb Ledell has joined the Company as Chief Operating Officer
(COO). Mr. Ledell is an accomplished public company COO with a
track record of driving operational excellence and strategic growth
within the biotechnology industry.
“I am pleased to welcome Jeb to KalVista at this key time in our
evolution. His extensive experience in leading teams and driving
efficiency within companies like ours makes him a valued addition
to the team as we continue to evolve into a commercial entity,”
said Ben Palleiko, Chief Executive Officer of KalVista. “I am
confident that his proven skills will help us to achieve our goal
of delivering sebetralstat to help transform the lives of people
living with hereditary angioedema.”
“I am excited to join the talented team at KalVista as the
Company prepares to launch sebetralstat on a global scale,” said
Mr. Ledell. “I am eager to contribute my insights and experience to
drive forward the Company’s mission of delivering a transformative
new therapy for those impacted by hereditary angioedema.”
Mr. Ledell has more than 20 years of leadership and operational
experience in the biotechnology industry, specializing in driving
organizational growth, optimizing processes, and overseeing complex
projects from inception to successful execution. He joins KalVista
from AVEO Oncology, an LG Chem company, where he held the same role
and oversaw AVEO’s operational strategy. Prior to AVEO, Mr. Ledell
served as COO at Enzyvant Therapeutics, where he played a key role
in the successful U.S. Food and Drug Administration approval of
RETHYMIC®. He has also held leadership positions at Compass
Therapeutics and Horizon Discovery Group, guiding both companies
through significant operational growth and transformation.
Mr. Ledell holds a B.S. in Chemical Engineering from Worcester
Polytechnic Institute.
On December 16, 2024, Mr. Ledell was granted inducement options
to purchase 100,000 shares of the Company’s Common Stock as an
inducement to Ledell’s entering into employment with KalVista. The
options were granted in accordance with Nasdaq Listing Rule
5635(c)(4) as inducements material to Mr. Ledell entering into
employment with the Company. The options will have an exercise
price equal to the closing price of the Company’s Common Stock on
the Nasdaq Stock Market LLC on the grant date of December 16, 2024.
The options will vest over a four year period with (i) 1/4th of the
total shares subject to the options vesting on the one year
anniversary of Mr. Ledell’s start date and (ii) thereafter, 1/48th
of the total number of shares underlying the options vesting on
each monthly anniversary of the vesting commencement date, which is
subject to Mr. Ledell’s continued service through each vesting
date. Each stock option has a 10-year term and is subject to the
terms and conditions of the Company’s 2021 Amended and Restated
Inducement Plan and a stock option agreement covering the
grant.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical
company whose mission is to develop and deliver life-changing oral
medicines for people affected by rare diseases with significant
unmet needs. Sebetralstat, our novel, investigational candidate for
the oral, on-demand treatment of hereditary angioedema, is under
regulatory review by the FDA with a PDUFA goal date of June 17,
2025. We have also completed Marketing Authorization Applications
for sebetralstat to the European Medicines Agency and multiple
other countries. For more information, please visit
www.kalvista.com or follow us on social media at @KalVista and
LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including our
KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2024, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241216320285/en/
Media: Jenn Snyder Vice President, Corporate Affairs
(857) 356-0479 jennifer.snyder@kalvista.com
Investors: Ryan Baker Head, Investor Relations (617)
771-5001 ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
